A Double-blind randomized placebo-controlled of memantine added to bipolar mood disorder treatment in obsession symptoms in patients with OCD

Status

Active, not recruiting

Phases

Phase 2

Study type

Interventional

Source

IRCT

Registry ID

IRCT201410073930N36

Enrollment

Registered

2014-11-01

Start date

2014-09-26

Completion date

Unknown

Last updated

2018-02-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Obsessive-compulsive disorder sumptoms. Obsessive-compulsive disorder

Interventions

Intervention 1: Lithium (up to 1200mg/day)+olanzapine (up to 25mg/day)+clonazepan (up to 2 mg/day)+ Memantine (up to 20 mg/day). Intervention 2: Lithium (up to 1200mg/day)+olanzapine (up to 25mg/day)+

Treatment - Drugs

Lithium (up to 1200mg/day)+olanzapine (up to 25mg/day)+clonazepan (up to 2 mg/day)+ Memantine (up to 20 mg/day)

Lithium (up to 1200mg/day)+olanzapine (up to 25mg/day)+clonazepan (up to 2 mg/day)+ Placebo

Eligibility

Sex/Gender

All

Age

16 Years to 65 Years

Inclusion criteria

Inclusion criteria: Inclusion criteria: obsessive compulsive disorder symptoms, YBOC >16. Exclusion criteria: acute phase of mania or depression, serious uncontrolled medical condition, pregnancy.

Exclusion criteria

Exclusion criteria:

Design outcomes

Primary

Measure	Time frame
Obsessive-Compulsive symptoms. Timepoint: Baseline, week4, week 8, week 16. Method of measurement: Yale-Brown Obsessive-Compulsive Scale.	—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactAli Sahraian

Shiraz University of Medical sciences

sahraian@sums.ac.ir00

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026